Clinical and demographic characteristics of study samples
| Group; no. (%)* | ||||
|---|---|---|---|---|
| Characteristic | Study sample, cognitive data n = 173 | Study sample, imaging data n = 82 | rs1938526 AA n = 147 | rs1938526 G carrier n = 26 |
| Male sex | 132 (76) | 61 (74) | 119 (80) | 14 (54)† |
| Age at cognitive testing, mean (range) yr | 22.8 (16–31) | 23.7 (18–31) | 22. (16–31) | 23. (18–28) |
| Education, mean (SD) yr | 11.3 (2.4) | 11.9 (2.4) | 11.3 (2.3) | 10.8 (2.7) |
| Diagnosis | ||||
| Nonaffective psychosis | 138 (80) | 69 (84) | 118 (80) | 20 (77) |
| Schizophrenia | 102 (59) | 50 (61) | 89 (61) | 13 (50) |
| Bipolar disorder | 24 (14) | 10 (12) | 22 (15) | 2 (8) |
| Age at onset of psychosis, median (range) yr | 21.2 (13–31) | 22.1 (15–31) | 21.1 (13–31) | 21.3 (14–27) |
| White race | 102 (59) | 55 (68) | 90 (61) | 13 (50) |
| Cognition tested in mother tongue | 136 (79) | 67 (83) | 120 (82) | 16 (62)† |
| Lifetime substance-use disorder diagnosis | 116 (67) | 53 (65) | 101 (69) | 15 (60) |
| Taking antipsychotics at cognitive testing | 139 (95) | 69 (97) | 114 (94) | 24 (92) |
| Chlorpromazine equivalents at cognitive testing, mean (SD) | 237 (241) | 210 (185) | 235 (252) | 246 (186) |
| Full scale IQ, mean (SD) | 92.6 (15.7) | 95.3 (14.5) | 94.1 (15.8) | 84.5 (13.2)‡ |